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ABSTRACT 
Total human chorionic gonadotropin (hCG) is high in maternal serum at 14-18 weeks of 
trisomy 21 (T21)-affected pregnancy, despite low placental hCG synthesis. We sought an 
explanation for this paradox. We first observed that in T21-affected pregnancies, maternal 
serum hCG levels peaked at around 10 weeks and then followed the same pattern throughout 
pregnancy as in controls, albeit at a higher (2.2-fold) level. After delivery hCG clearance was 
not significantly different from that in controls. We isolated cytotrophoblasts from 29 T21- 
affected placentas (12-25 weeks) and 13 gestational age- matched control placentas and 
cultured them for 3 days. In this large series we confirmed that in the culture medium of 
trophoblasts isolated from T21 placentas, hCG secretion was significantly lower (p <0.003) 
than in controls, in contrast to the high hCG in maternal serum of the same patients. In T21 
cultured trophoblasts, transcripts of sialyltransferase-1 and fucosyltransferase-1 were 
abnormally high. In corresponding culture medium, hCG was abnormally glycosylated, 
highly acidic (pHi = 4.5) as shown by isoelectric focusing, immunoblotting and lectin binding 
and weakly bioactive (46% of control) as determined using the Leydig cell model. In 
conclusion, T21 trophoblast cells produced hCG that was weakly bioactive and abnormally 
glycosylated, but whose maternal clearance was unaltered.  
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INTRODUCTION  
 Trisomy of chromosome 21 (T21), which causes the phenotype known as Down 
syndrome, is the major known genetic cause of mental retardation and is found in 
around 1:800 live births. Screening strategies to identify women at increased risk of 
bearing a T21-fetus are based on maternal age, ultrasound signs (1) and maternal 
serum marker (2-5). Some of these markers, such as hCG, are of placental origin. 
When the fetus is trisomy 21-affected, it is now well established that total human 
chorionic gonadotropin (hCG) or its free ß subunit are raised (2 to 2.2 MoM) in 
maternal serum at 14-18 weeks of pregnancy. However, despite its widespread 
clinical use, the pathophysiology of this increase remains largely unknown.  
hCG is composed of two subunits, one alpha common to all glycoprotein hormones 
(FSH, LH and TSH), and one specific beta subunit. The alpha subunit is a 92-amino-
acid polypeptide with two N-linked oligosaccharides. The specific beta subunit is a 
145-amino-acid polypeptide with two N-linked oligosaccharides and four O-linked 
oligosaccharides (6). 
hCG is synthesized by the trophoblast, mainly by the  syncytiotrophoblast, the outer 
layer of the chorionic villus (7). The syncytiotrophoblast is a very active endocrine 
unit, which secretes the vast majority of its hormonal products into the maternal 
circulation. The syncytiotrophoblast arises in vivo (8) and in vitro (9) from 
differentiation of cytotrophoblasts.  
In trisomy 21, we recently confirmed previous observations by Eldar-Geva (10) that 
cultured cytotrophoblasts, isolated from trisomy 21-affected placentas, aggregate but 
fuse poorly or tardily (11). This is in agreement with previous macroscopic and 
histological observations pointing to an increase in the cytotrophoblast layer in 
trisomy 21 placentas (12-14). In addition, we demonstrated that this in vitro defect or 
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delay in syncytiotrophoblast formation and function is characterized by a dramatic 
decrease in the synthesis and secretion of syncytiotrophoblastic pregnancy-
associated hormones such as hCG, human placental lactogen (hPL), and human 
placental growth hormone (hPGH) (11,15).  Similarly, we observed a significant 
decrease in mRNA levels of these hormones in trisomy 21 total placenta extracts, 
indicating a decrease in functional syncytiotrophoblast mass in trisomy 21-affected 
placenta (11). 
In summary, trisomy 21-affected placenta presents morphological and functional 
anomalies, which result in a decrease in pregnancy-associated hormone production 
by the syncytiotrophoblast. Therefore, there is a discrepancy between the abnormally 
high maternal serum hCG values and the low placental rate of hCG synthesis. The 
aim of this study was to find an explanation for this paradox. 
 
MATERIALS AND METHODS 
 
Maternal sera and placental tissue collection 
  
 Since 1988, maternal serum samples have been collected at the Hôpital 
Ambroise Paré from women included in second-trimester trisomy 21 maternal serum 
screening. In addition, all pregnant women in France undergo first-trimester maternal 
serum screening for toxoplasmosis. During the third trimester blood samples were 
taken in the case of abnormal ultrasound findings. The resulting serum samples were 
stored frozen at -20°C. Moreover, since 1996 maternal serum samples have been 
collected from women prior to termination of trisomy 21-affected pregnancy. French 
law allows termination of pregnancy with no gestational age limit when severe fetal 
abnormalities are observed. Trisomy 21 was diagnosed by karyotyping. The 
H
AL author m
anuscript    inserm
-00128419, version 1
 5 
indications for chorionic villus sampling, amniocentesis or fetal blood sampling were 
advanced maternal age, ultrasound abnormalities or abnormal maternal serum 
markers. Demographic and pregnancy-related information (maternal age, weight, and 
gestational age at sampling) were entered in a database.  
Samples of placental tissues were collected at the time of termination of pregnancy at 
12-25 weeks of gestation (in weeks of amenorrhea) in trisomy 21-affected 
pregnancies and gestational age-matched control cases. Gestational age was 
confirmed by ultrasound measurement of crown-rump length at 8-12 weeks of 
gestation. Fetal Down syndrome was diagnosed by karyotyping of amniotic fluid cells, 
chorionic villi or fetal blood cells. Termination of pregnancy was performed in control 
cases affected by severe bilateral or low obstructive uropathy or major cardiac 
abnormalities.The karyotype of placental cells was checked in all cases (free trisomy 
21 or normal). 
For maternal serum hCG clearance, maternal blood samples were taken at the 
indicated times after delivery (placental expulsion) in 9 T21 pregnancies (free T21) 
and in 8 gestational age-matched controls (second trimester of pregnancy, fetus with 
severe bilateral uropathy or major cardiac abnormalities and normal karyotype). 
Informed consent was obtained in all cases. The resulting serum samples were 
stored frozen at -20°C. 
 
Trophoblast cell culture 
Villous cytotrophoblast culture was undertaken as previously described (11). 
Cytotrophoblasts were isolated from gestational age-matched controls (second 
trimester) and trisomy 21-affected placentas and cultured for three days. For each 
culture, cells were plated on 3 dishes. The culture medium of each dish was changed 
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every 24 hours, collected and assayed for hormonal concentrations. The mean value 
of triplicates was calculated and was representative of hCG secretion at 72 hours. 
This was done for the 29 T21 cultures and the 13 control cultures.  
 
RNA isolation and analysis 
Total RNA was extracted from placental tissues and cultured cells following 
the procedure of QIAGEN (Courtabeuf, France). The total RNA concentration was 
determined at 260 nm and its integrity was monitored by 1% agarose gel 
electrophoresis.  
Beta hCG transcript levels were quantified in total placental homogenates as 
previously described (16). Sialyl-transferase mRNA and fucosyl-tranferase mRNA 
levels were measured in cultured cells. Three dishes were pooled for each 
determination by quantitative RT-PCR assay as previously described (16). The 
nucleotide sequences of the primers are the following:available upon request 
(mvidaud@teaser.fr). The levels of transcripts were normalized using the RPLP0 
gene (also known as 36B4) encoding human acidic ribosomal phosphoprotein P0 as 
an endogenous RNA control. The 24 h conditioned culture medium was collected at 
day three and frozen. 
 
Affinity chromatographies 
 Lectin-affinity chromatographies were used to analyze glycosylation of total 
hCG in culture medium: 1) Triticum vulgaris which recognizes the N-acetyl glucose 
and sialyl groups of glycoproteins; 2) Tetragonolobus purpureas which recognizes 
alpha-fucosyl groups; 3) Ricinus communis which recognizes ß-galactosyl groups; 4) 
Concanavalin A a lectin which recognizes biantennary structures but neither tri- or 
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tetra-antennary structures nor biantennary structures of glycoproteins. Samples were 
applied to 0.5 ml columns of lectin (10 ml/h, room temperature) as described by 
Baenziger and Fiete (17). The first fraction, not bound by the lectin, was eluted in the 
starting buffer and the second fraction (lectin-bound) with starting buffer 
supplemented with 0.2 M of the lectin-specific ose. HCG was assayed in each 
fraction.  
Isoelectrofocusing (IEF) was performed as previously described (18) using a 
monoclonal antibody against free ß-hCG (Ab FBT10, generous gift of Pr. J-M Bidart, 
Institut Gustave Roussy, Villejuif, France) (19). 
 
Hormone assay 
Total hCG was measured in culture media and maternal serum using the ACS180SE 
instrument (Bayer, Fernwald, Germany). 
 
hCG biological activity assay 
Biological activity of secreted hCG was tested on Leydig cells (MA.10 cells, generous 
gift of Pr. M. Ascoli, University of Iowa, Iowa City, USA) as previously described (20). 
hCG levels were first assayed in the culture medium of trophoblasts. Different 
amounts of culture medium were added for 4 h to 2.106 MA-10 cells cultured on 
gelatin-coated 30 mm dishes. Progesterone was then assayed in the MA-10 cell 
incubation medium. Results were expressed as progesterone concentration per 
number of cells for each tested concentration of hCG present in the control and T21 
trophoblast culture medium. Progesterone was assayed using the ACS180SE 
instrument (Bayer, Fernwald, Germany). 
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Statistical analysis 
Statistical analysis was performed using the Statview F4.5 software package 
(Abacus Concept, Inc ; Berkleley, CA, USA). Values are presented as the mean± 
SEM. Comparisons were performed using Student’s t-test. p<0.05 was considered 
significant.  
 
 
RESULTS 
 
Maternal serum hCG levels 
 Maternal serum hCG levels were analyzed throughout pregnancy in a large cohort of 
control and T21-affected pregnancies (figure 1). We confirmed that, in trisomy 21 
cases, hCG levels were increased during the periods 7-13 weeks and 14-18 weeks. 
In addition, we observed that the hCG levels peaked around 10 weeks in both 
trisomy 21 and control cases, with no gap between the two peaks. Moreover, we 
noted that this increase continued during the third trimester. The discrepancies 
between MoMs in normal (1 MoM) and trisomy 21-affected cases (2.16 MoM) were 
approximately constant throughout gestation. 
 
Trophoblast culture 
We confirmed in a large series of primary cultures the significant (p = 0.003) 
decrease in hCG secretion in the culture medium of trophoblast cells isolated from 
T21 placentas (n = 29, mean ± SEM: 337 ± 62 IU/L) as compared to gestational age-
matched control placentas (n = 13, mean ± SEM: 930 ± 246). Likewise, as previously 
described (11),  we confirmed in this series that in the total homogenates of the 
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corresponding placentas the transcript levels of beta hCG measured by real-time 
quantitative RT-PCR were significantly decreased (p<0.01) in T21-affected placentas 
(mean ± SEM: 4139 ± 1554) as compared to controls (mean ± SEM: 19494 ± 5812). 
In contrast, hCG levels in maternal serum corresponding to these placentas were 
significantly higher (p <0.0001) in trisomy 21-affected pregnancies (median of MoM = 
2.3) than in control pregnancies (median MoM = 1.0).  
 
Maternal serum hCG clearance 
We studied the disappearance of hCG in the maternal serum after delivery and 
therefore after expulsion of the placenta. The percentage of hCG remaining in 
maternal circulation at different times after delivery (table 1) was not significantly 
different between normal and T21-affected pregnancies. 
 
hCG bioactivity 
We tested the ability of culture medium from normal and trisomy 21 trophoblasts to 
stimulate steroid production in Leydig cells possessing LH receptors, which bind 
hCG. At equal concentration of hCG in the culture medium (10-10 M), the ability of 
culture media of trisomy 21 trophoblasts to stimulate Leydig cell progesterone 
secretion was significantly (p < 0.0008) decreased (figure 2). 
 
Trophoblast glycosylation activity 
mRNA levels of two enzymes involved in the glycosylation pathway, sialyl-
transferase-1 (which adds a sialyl group to antennary structures) and fucosyl-
transferase-1 (which adds a fucose to the first N-acetyl-glucosamine of 
glycoproteins), were significantly higher (p <0.05) in cultured trophoblasts isolated 
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from trisomy 21 placenta (n = 5) than in control cases (n = 5) (mean ± SEM: 27 ±15 
vs 2.5 ± 1 and 9 ± 3 vs 3 ± 1, respectively). Lectin binding differed between hCG 
secreted by normal and trisomy 21 trophoblast cultures (table 2). IEF and 
immunobloting (figure 3) of hCG present in culture medium from normal trophoblasts 
revealed a band with a pHi at 7.3, whereas in culture medium from T21 trophoblast a 
more acid band (pHi = 4.5) was present. 
 
DISCUSSION  
 The major endocrine component of human placenta is the villous trophoblast 
and mainly the syncytiotrophoblast, which arises in vivo and in vitro from fusion of 
mononucleated cytotrophoblasts. We previously demonstrated in vitro (11, 15), and 
confirmed in the present study in a large number of primary trophoblast cultures (n = 
29), that in trisomy 21-affected placenta formation of syncytiotrophoblast is defective 
or delayed. The genetic overexpression of copper-zinc superoxide dismutase is 
involved in this abnormal trophoblast fusion and differentiation (16). These results are 
in agreement with previous macroscopic and histological observations of T21-
affected placentas which reveal delayed maturation of chorionic villi and 
syncytiotrophoblastic hypoplasia with a persistent cytotrophoblastic layer in the third 
trimester (12,14). They point to a decrease in the syncytiotrophoblast mass in T21-
affected placentas and therefore to a decrease in hCG synthesis. We confirmed in 
this study our previous observation of a significant decrease in hCG transcript levels 
in total placental homogenats from T21-affected placentas as compared to 
gestational age-matched controls. These results do not agree with previous 
observations of different authors describing increased or no change in hCG transcript 
levels or protein levels. Eldar-Geva (10) reported an increase in hCGα and hCGβ 
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mRNA in trophoblast cells of T21-affected placenta. This was based on a northern 
analysis performed with cells cultured for 24hours. In this study the secretion of hCG 
at 24 hours is extremely variable from one T21 cell culture to another one. In addition 
the secretion of hCG at 24 hours in normal cells or in T21 cells is higher than the one 
observed at 72h and 96h. This suggests a contamination of cytotrophoblast cell 
cultures by fragments of syncytiotrophoblast, which explains the highest transcript 
levels of hCG. Indeed it is now well established that hCG transcript levels and hCG 
secretion are higher in the syncytiotrophoblast as compared to the cytotrophoblasts 
(9, 21-24). Jauniaux et al (25) and Newby et al (26) have compared the levels of hCG 
and/or of its free subunits, detected by immunoassay in placental total homogenate 
extracts. This is a different methodological approach, focused on the protein levels 
and thereby depending upon the specificity of the antibodies. In addition total 
placental extracts are contaminated by maternal blood which may lead to artefactual 
increase in hCG levels and therefore do not directly reflect the trophoblast synthesis 
of hCG. In addition, Newby et al, did not find an increase in hCG by 
immunohistochemistry. 
 The defect in trophoblast differentiation pointing to a delayed placental 
maturation in T21 prompted us first to check that the increased hCG levels observed 
during first- and second-trimester maternal screening are not related to a delay in the 
physiological peak of hCG in the maternal circulation. In normal pregnancies, hCG 
concentrations rise rapidly in maternal serum, peaking at 9-10 weeks of gestation, 
followed by a fall during the second trimester. The factors involved in the peak of 
hCG during pregnancy are widely debated and remain to be elucidated (see 27 for 
review). Maternal serum hCG peaked in trisomy 21-affected pregnancies at exactly 
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the same time (10 weeks) as in normal pregnancies and these high levels of hCG 
persisted throughout pregnancy in the case of trisomy 21.  
The discrepancy between decreased placental hCG production and high 
maternal serum levels in T21-affected pregnancies points to an abnormal clearance 
of this hormone in the maternal-placental compartment. Maternal serum hCG 
clearance depends on maternal hepatic catabolism, renal excretion, ovarian uptake 
and placental uptake. In this study we observed that after placental expulsion, the 
disappearance of hCG in the maternal serum was similar in normal and T21-affected 
pregnancies. This suggested that in the absence of placenta, the clearance of hCG in 
the maternal compartment was the same. Therefore this pointed to an abnormal 
placental hCG clearance in T21-affected pregnancies. In addition, we observed for 
the first time that hCG produced by T21-affected trophoblasts had a low bioactivity, 
as shown by the well- established Leydig cell assay (20). Therefore, hCG produced 
by T21-affected trophoblasts will have little ability to stimulate the LH/hCG receptors 
in its main target organs, and therefore in the placenta. Indeed, the placenta is an 
organ which possesses a large number of hCG receptors (28) and hCG plays a 
major role via an autocrine process in trophoblastic differentiation (29-31). 
Furthermore, the placenta presents a large surface of exchange due to the presence 
of microvilli at the surface of the syncytiotrophoblast bathing in the maternal blood. 
This favors the capture of circulating maternal hCG by trophoblast receptors (13). 
Therefore, the increased maternal hCG levels observed in T21-affected pregnancies 
might be related to different abnormalities: 1/ a decreased number of hCG receptors 
in T21-affected placentas or an abnormality of these receptors. hCG receptors in 
T21-affected placentas are poorly known. However, an increase in receptor gene 
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expression has been described in these placentas (25). 2/ a decreased binding 
and/or internalization of this low bioactive hCG secreted by T21-affected trophoblast.   
 
 HCG is a complex glycoprotein hormone whose molecular size and 
carbohydrate content change in physiological processes (gestation) or in pathological 
conditions such as choriocarcinoma (32-35). Based on the use of a monoclonal 
antibody (B152 hCG) raised against the hyperglycosylated choriocarcinoma hCG, a 
hyperglycosylated isoform produced by the first-trimester cytotrophoblast cells (but 
not syncytiotrophoblast) can be detected in the maternal blood and urine only during 
the first 6-7 weeks of pregnancy (36-38). Cole et al. investigated the composition of 
the N-linked and O-linked oligosaccharide side chains in hCG. In Down syndrome 
pregnancies, hyperglycosylated hCG (H-hCG), also called invasive trophoblast 
antigen (ITA), was found in maternal serum and urine in higher proportion than in 
controls, and its measurement was proposed as a potential alternative to hCG in 
Down syndrome screening during the first or second trimester (39-46). 
 In the present work, for the first time, hCG glycosylation was studied 
comparatively at the source of hormone production, ie cultured trophoblast cells from 
age-matched second-trimester control and T21-affected placentas. The 
demonstration of an abnormally glycosylated hCG synthesized by trisomy 21 
placental cells was based on: 1) fucosyl-transferase-1 and sialyl-tranferase-1 
transcript increases in T21 trophoblast cells; 2) different binding of the secreted hCG 
to different lectins, 3) detection by IEF of a highly acidic form of hCG in the T21 cell 
culture medium. The IEF pattern reflects the heterogeneity of the charged sugar 
(sialic acid), which varies with the multi-antennarity and/or moiety of the N- or O-
oligosaccharide chains in which sialic acid is the terminal sugar. Glycosylation 
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modification of polypeptide hormones is known to modulate their activity on target 
cells. Interestingly, this T21-hCG had a low bioactivity as compared to hCG secreted 
by gestational age control trophoblasts.  
In conclusion due to the pleiotropic role of this hormone in human pregnancy, 
maintenance of corpus luteum, trophoblast differentiation, endometrium 
vascularization, etc. (7,47) these results suggest that this abnormal highly 
glycosylated weakly bioactive hCG might be implicated in the highly frequent 
spontaneous abortion observed in this aneuploidy. 
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Legends of figures 
 
Figure 1. Transversal study of maternal serum levels as a function of gestational age 
of total hCG (control cases: n = 894; trisomy 21: n = 499).  
Empty circle = controls; black triangle = trisomy 21-affected pregnancy. Each point 
represents a single measurement for one patient.  Inset shows median values. 
 
Figure 2. Bioactivity of hCG secreted by normal and T21 trophoblast cells. hCG 
produced by trophoblast cells was measured by immunoassay in conditioned media 
from cultures of control (n = 5) and T21 trophoblasts (n = 5). Different volumes of 
these media corresponding to the indicated concentrations of hCG were added to 
MA-10 Leydig cell culture. Progesterone was assayed in MA-10 culture media 3 
hours later. 
*p < 0.05; ***p < 0.001 
 
Figure 3. hCG isoforms secreted by normal (n = 3) and T21 trophoblast cells (n = 3) 
as revealed by isofocusing and immunoblot.  
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Hours Control T21
3 63%  ±11 48%  ±9
(n = 3) (n = 3)
6 51%  ±17 45%  ±0.03
(n = 5) (n = 3)
12 37%  ±12 28%  ±6
(n = 8) (n = 9)
24 22%  ±9 17% ±5
(n = 7) (n = 9)
Table 1. Percentage of hCG in maternal sera at different times after 
delivery as compared to the values observed 24 h before expulsion.
Lectin Control Trisomy 21
Triticum vulgaris 89.5% ±4.8 93.9% ±3.5 
Tetragonolobus purpurea 1.4% ±0.5 7.7% ±3.6 *
Ricinus communis 5.7% ±1.4 18.8% ±6.5 *
Concanavalin A 96.8% ±1.8 81.6% ±2 *
Table 2. Glycosylation analysis of hCG in culture medium of 5 different  
72-hour trophoblast cell cultures.  
Lectin-bound fractions are expressed as a % of the total fraction (mean ± SD). 
 * p < 0.05
